SCHEMBL1798505

SCHEMBL1798505

CN(CC(=O)Nc1ccc(Cl)cc1C(=O)O)CC(=O)N1CCN(C(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.71
CACNA2D1 P54289 11/20 0.53
CACNB1 Q02641 11/20 0.53
CACNA1B Q00975 10/20 0.53
CACNA1G O43497 9/20 0.49
CACNA1C Q13936 4/20 0.49
CACNA1A O00555 1/20 0.48
ALDH1A1 P00352 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1796719 0.92 SERPINE1 (0.63) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
SCHEMBL1798040 0.84 SERPINE1 (0.75) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
SCHEMBL1799473 0.83 SERPINE1 (0.73) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
SCHEMBL1798984 0.83 SERPINE1 (1.00) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
Hydrochloric Acid SCHEMBL1800586 0.82 SERPINE1 (0.72) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
SCHEMBL1799860 0.82 SERPINE1 (0.98) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
SCHEMBL29351719 0.82 SERPINE1 (0.98) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
SCHEMBL539165 0.81 SERPINE1 (0.70) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G
SCHEMBL418105 0.80 SERPINE1 (0.69) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1C
Hydrochloric Acid SCHEMBL416268 0.80 SERPINE1 (0.68) SERPINE1CACNA2D1CACNB1CACNA1BCACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US claimed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US claimed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885CACNA2D1 3723/4885CACNB1 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.